Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
UroGen Pharma Ltd. - Ordinary Shares
(NQ:
URGN
)
19.91
-0.55 (-2.69%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 9, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about UroGen Pharma Ltd. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
UroGen Pharma Ltd. (URGN) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
May 19, 2025
From
Law Offices of Howard G. Smith
Via
Business Wire
Securities Fraud Investigation Into UroGen Pharma Ltd. (URGN) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
May 16, 2025
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
↗
May 16, 2025
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Via
Chartmill
Earnings Scheduled For May 12, 2025
↗
May 12, 2025
Via
Benzinga
A Look at UroGen Pharma's Upcoming Earnings Report
↗
May 09, 2025
Via
Benzinga
Top stock movements in today's session.
↗
May 16, 2025
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via
Chartmill
The market is filled with gapping stocks in Friday's session.
↗
May 16, 2025
Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via
Chartmill
UroGen Pharma Reports First Quarter 2025 Financial Results and Provides a Business Update
May 12, 2025
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Announces FDA Advisory Committee for UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
May 07, 2025
From
UroGen
Via
Business Wire
UroGen Pharma to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
May 01, 2025
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates
↗
April 28, 2025
UroGen Pharma reports strong long-term data for Jelmyto and UGN-102 in cancer studies and shares promising early results for UGN-301 in bladder cancer.
Via
Benzinga
Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday
↗
April 28, 2025
Via
Benzinga
OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment
April 27, 2025
From
UroGen Pharma Ltd.
Via
Business Wire
New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC
April 27, 2025
From
UroGen Pharma Ltd.
Via
Business Wire
New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC
April 27, 2025
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
April 26, 2025
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer
April 26, 2025
From
UroGen Pharma Ltd.
Via
Business Wire
This H.B. Fuller Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
↗
April 17, 2025
Via
Benzinga
This UroGen Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
↗
April 16, 2025
Via
Benzinga
UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers
April 14, 2025
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102
March 10, 2025
From
UroGen Pharma Ltd.
Via
Business Wire
Earnings Scheduled For March 10, 2025
↗
March 10, 2025
Via
Benzinga
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 07, 2025
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025
February 27, 2025
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference
February 24, 2025
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations
February 20, 2025
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Ltd. (NASDAQ: URGN), CS Diagnostics Corp. (OTCQB: CSDX) and Boston Scientific (NYSE: BSX) Advancing Cancer Treatment Technology – More Stocks Inside
February 19, 2025
Via
AB Newswire
UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102
February 14, 2025
From
UroGen Pharma Ltd.
Via
Business Wire
Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology
February 12, 2025
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Present at Upcoming Investor Conferences
January 30, 2025
From
UroGen Pharma Ltd.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
